Awaiting product image

HPV vaccine (cervavac)

₹2,000.00

CERVAVAC® is indicated in girls and women 9 through 26 years of age for the prevention of the following diseases caused by Human Papillomavirus (HPV) types, included in the vaccine:

  • Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16 and 18.
  • Genital warts (condyloma acuminata) caused by HPV types 6 and 11.
Category:

Description

DOSAGE

Individuals 9 to 14 years of age –
CERVAVAC® should be administered according to a 2-dose schedule (0.5 ml at 0, 6 months).
Individuals 15 to 26 years of age CERVAVAC® should be administered according to a 3-dose (0.5 ml at 0, 2, 6 months) schedule.
The second dose should be administered at least one month after the first dose and the third dose should be administered at least 3 months after the second dose. All three doses should be given within a 1-year period.
The use of CERVAVAC® should be in accordance with official recommendations.
Paediatric population –
The safety and efficacy of CERVAVAC® in children below 9 years of age have not been established. No data are available.
It is recommended that individuals who receive a first dose of CERVAVAC® complete the vaccination course with CERVAVAC®.
The need for a booster dose has not been established.

Related Products